Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
There's still a lot of optimism in Indian assets, says David Roche
06:15am, Wednesday, 05'th Jun 2024
David Roche, strategist at Quantum Strategy, discusses India's election results.
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
12:30pm, Wednesday, 29'th May 2024
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
01:00am, Wednesday, 29'th May 2024
Basel, 29 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application and granted Priority Review to
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
01:00am, Monday, 27'th May 2024
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwide Upcoming launches of
Changes to the Roche Enlarged Corporate Executive Committee
01:00am, Monday, 27'th May 2024
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company.
Analog Devices CEO Vincent Roche on Q2 earnings
12:30pm, Wednesday, 22'nd May 2024
Analog Devices CEO Vincent Roche joins CNBC's 'Money Movers' to discuss the company's earnings report, implementing AI, and more.
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
01:00am, Wednesday, 22'nd May 2024
Basel, 22 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Admi
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
12:41pm, Tuesday, 21'st May 2024
Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthr
Basel, 21 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational
Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
12:40pm, Monday, 20'th May 2024
Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mar
GLP-1 Drug Development Market Pile-Up Continues
08:20am, Monday, 20'th May 2024
The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced pos
Roche Is Joining The Obesity Party But Questions Remain
11:18am, Saturday, 18'th May 2024
Roche's obesity candidate CT-388 showed positive results in a phase 1b trial, with an 18.8% placebo-adjusted weight loss at week 24. The full data presentation is needed to assess safety and tolerabil
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
11:06am, Friday, 17'th May 2024
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this s
